Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35


Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, Beaumont D, Shen X, Yates NL, Pinter A, Tomaras GD, Ferrari G, Montefiori DC, Hu SL.

J Virol. 2016 Sep 12;90(19):8644-60. doi: 10.1128/JVI.00853-16.


Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.

Thippeshappa R, Tian B, Cleveland B, Guo W, Polacino P, Hu SL.

Clin Vaccine Immunol. 2015 Dec 30;23(3):204-12. doi: 10.1128/CVI.00597-15.


What Has 30 Years of HIV Vaccine Research Taught Us?

Esparza J.

Vaccines (Basel). 2013 Oct 30;1(4):513-26. doi: 10.3390/vaccines1040513.


Advances in antiviral vaccine development.

Graham BS.

Immunol Rev. 2013 Sep;255(1):230-42. doi: 10.1111/imr.12098. Review.


A Multi-Vector, Multi-Envelope HIV-1 Vaccine.

Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Jones B, Surman S, Sealy R, Freiden P, Branum K, Slobod KS.

J Pediatr Pharmacol Ther. 2007 Apr;12(2):68-76. doi: 10.5863/1551-6776-12.2.68.


Poxvirus vectors as HIV/AIDS vaccines in humans.

Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M.

Hum Vaccin Immunother. 2012 Sep;8(9):1192-207. doi: 10.4161/hv.20778. Review.


Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 009 Study Team.; VRC 010 Study Team..

PLoS One. 2010 Feb 2;5(2):e9015. doi: 10.1371/journal.pone.0009015.


What does the report of the USMHRP Phase III study in Thailand mean for HIV and for vaccine developers?

Graham BS.

Clin Exp Immunol. 2009 Dec;158(3):257-9. doi: 10.1111/j.1365-2249.2009.04055.x. No abstract available.


Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network..

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):203-12.


Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Haynes BF, Montefiori DC.

Expert Rev Vaccines. 2006 Jun;5(3):347-63. Review.


Non-human primate models for AIDS vaccine research.

Hu SL.

Curr Drug Targets Infect Disord. 2005 Jun;5(2):193-201. Review.


Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads.

Nag P, Kim J, Sapiega V, Landay AL, Bremer JW, Mestecky J, Reichelderfer P, Kovacs A, Cohn J, Weiser B, Baum LL.

J Infect Dis. 2004 Dec 1;190(11):1970-8.


Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.

Cho MW, Kim YB, Lee MK, Gupta KC, Ross W, Plishka R, Buckler-White A, Igarashi T, Theodore T, Byrum R, Kemp C, Montefiori DC, Martin MA.

J Virol. 2001 Mar;75(5):2224-34.


Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA, Wild C, Lifson J, Moss B.

J Virol. 2001 Jan;75(2):645-53.


Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.

Richmond JF, Lu S, Santoro JC, Weng J, Hu SL, Montefiori DC, Robinson HL.

J Virol. 1998 Nov;72(11):9092-100.


Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

Benson J, Chougnet C, Robert-Guroff M, Montefiori D, Markham P, Shearer G, Gallo RC, Cranage M, Paoletti E, Limbach K, Venzon D, Tartaglia J, Franchini G.

J Virol. 1998 May;72(5):4170-82.

Items per page

Supplemental Content

Support Center